Table 3 Apheresis outcomes for patients with initial CD34+ count ≤ 10 × 106 cells/µl
From: Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis
Pre-plerixafor era (n = 41) | Plerixafor era (n = 88) | p< | |||
|---|---|---|---|---|---|
Initial peripheral CD34+ (cells/µl) | |||||
Mean (SD) | 6.5 | (3.3) | 5.7 | (2.7) | |
Median (Q1–Q3) | 7.7 | (4.0–9.7) | 6.0 | (3.3–8.0) | |
Range (min–max) | (0.0–10.0) | (1.0–10.0) | 0.07 (b) | ||
Number of apheresis sessions | |||||
Mean (SD) | 2.2 | (0.9) | 1.6 | (0.6) | |
Median (Q1–Q3) | 2.0 | (2.0–2.0) | 2.0 | (1.0–2.0) | |
Range (min–max) | (1.0–5.0) | (1.0–4.0) | 0.001 (b) | ||
Total apheresis blood volume (l) | |||||
Mean (SD) | 27.1 | (13.8) | 19.6 | (10.7) | |
Median (Q1–Q3) | 23.9 | (19.3–33.7) | 17.6 | (11.6–24.0) | |
Range (min–max) | (4.5–68.9) | (4.1–67.0) | 0.001 (b) | ||
Total minutes of apheresis | |||||
Mean (SD) | 457 | (204) | 361 | (151) | |
Median (Q1–Q3) | 430 | (290–550) | 306 | (239–484) | |
Range (min–max) | (180–1065) | (150–732) | 0.01 (b) | ||
Estimated apheresis cost in € | |||||
Mean (SD) | 6174 | (2455) | 4622 | (1845) | |
Median (Q1–Q3) | 5688 | (5688–5688) | 5688 | (2844–5688) | |
Range (min–max) | (2844–14,220) | (2844–11,376) | 0.001 (b) | ||
CD34+ cells, total (x106 cells/kg) | |||||
Mean (SD) | 3.2 | (1.9) | 4.2 | (2.2) | |
Median (Q1–Q3) | 3.1 | (1.4–4.5) | 3.7 | (2.9–4.8) | |
Range (min–max) | (0.4–8.0) | (0.8–12.9) | 0.02 (b) | ||
CD34+ cells, first apheresis (x106 cells/kg) | |||||
Mean (SD) | 1.5 | (1.4) | 2.7 | (1.4) | |
Median (Q1–Q3) | 1.2 | (0.7–1.7) | 2.5 | (1.7–3.6) | |
Range (min–max) | (0.4–8.0) | (0.6–8.1) | 0.001 (b) | ||
